Answers are grounded in this paper and cite their sources.
Case descriptions reveal sotatercept may stabilize hereditary PVOD, indicating potential for lung transplantation support.
Background Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary arterial hypertension (PAH). Its prognosis is considerably worse and no medical treatment has a proven efficacy. Vasodilating drugs for PAH may contribute to a pulmonary edema in PVOD. Sotatercept is the latest approved medical treatment for PAH with a unique mode of action and promising treatment effects. However, none of the clinical trials of sotatercept have included patients with PVOD, so the effect of sotatercept is unknown. Case Description We report two cases of hereditary PVOD that were treated with sotatercept in addition to established pulmonary arterial hypertension therapy. Under treatment with sotatercept, both patients showed stabilization of clinical condition and gas exchange, accompanied by slight improvements in DLCOc and KCOc. Conclusions These two cases suggest that sotatercept may have a beneficial effect on disease stabilization in hereditary PVOD, as reflected by improvements in DLCOc and KCOc as well as stabilization of clinical status. Therefore, it may be a therapeutic option to stabilize patients with PVOD and potentially prolong the bridging time to lung transplantation.
No takes yet. Share an insight, caveat, or question.
Mietzner et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: